Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: Open-label, noncomparative, multicenter, long-term follow-up study.
AffiliationDivision of Neurology, Beaumont Hospital, Dublin, Ireland UCB Pharma, Raleigh,, North Carolina, U.S.A.1 UCB Pharma, Brussels, Belgium1.
MetadataShow full item record
CitationEpilepsia. 2012 Jan;53(1):111-9. doi: 10.1111/j.1528-1167.2011.03300.x. Epub 2011, Nov 2.
AbstractPurpose: To evaluate the long-term efficacy and tolerability of adjunctive levetiracetam (LEV) in patients with uncontrolled idiopathic generalized epilepsy (IGE). Methods: This phase III, open-label, long-term, follow-up study (N167; NCT00150748) enrolled patients (4 to <65 years) with primary generalized seizures (tonic-clonic, myoclonic, absence). Patients received adjunctive LEV at individualized doses (1,000-4,000 mg/day; 20-80 mg/kg/day for children/adolescents weighing <50 kg). Efficacy results are reported for all seizure types [intention-to-treat (ITT) population, N = 217] and subpopulations with tonic-clonic (n = 152), myoclonic (n = 121), and/or absence (n = 70) seizures at baseline. Key Findings: One hundred twenty-five (57.6%) of 217 patients were still receiving treatment at the end of the study. Mean (standard deviation, SD) LEV dose was 2,917.5 (562.9) mg/day. Median (Q1-Q3) exposure to LEV was 2.1 (1.5-2.8) years, and the maximum duration was 4.6 years. Most patients were taking one (124/217, 57.1%) or >/=2 (92/217, 42.4%) concomitant antiepileptic drugs (AEDs). Seizure freedom of >/=6 months (all seizure types; primary efficacy end point) was achieved by 122 (56.2%) of 217 patients, and 49 (22.6%) of 217 patients had complete seizure freedom. Seizure freedom of >/=6 months from tonic-clonic, myoclonic, and absence seizures was achieved by 95 (62.5%) of 152, 75 (62.0%) of 121, and 44 (62.9%) of 70 patients, respectively. Mean (SD) maximum seizure freedom duration was 371.7 (352.4) days. At least one treatment-emergent adverse event (TEAE) was reported by 165 (76%) of 217 patients; most TEAEs were mild/moderate in severity, with no indication of an increased incidence over time. Seventeen (7.8%) of 217 patients discontinued medication because of TEAEs. The most common psychiatric TEAEs were depression (16/217, 7.4%), insomnia (9/217, 4.1%), nervousness (8/217, 3.7%), and anxiety (7/217, 3.2%). Significance: Adjunctive LEV (range 1,000-4,000 mg/day) demonstrated efficacy as a long-term treatment for primary generalized seizures in children, adolescents, and adults with IGE, and was well tolerated.
- Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
- Authors: Trevathan E, Kerls SP, Hammer AE, Vuong A, Messenheimer JA
- Issue date: 2006 Aug
- Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study.
- Authors: Tsai JJ, Yen DJ, Hsih MS, Chen SS, Hiersemenzel R, Edrich P, Lai CW
- Issue date: 2006 Jan
- Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
- Authors: Callenbach PM, Arts WF, ten Houten R, Augustijn P, Gunning WB, Peeters EA, Weber AM, Stroink H, Geerts Y, Geerts AT, Brouwer OF
- Issue date: 2008 Jul
- An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
- Authors: Abou-Khalil B, Hemdal P, Privitera MD
- Issue date: 2003 Apr
- Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures.
- Authors: Baulac M, Brodie MJ, Elger CE, Krakow K, Stockis A, Meyvisch P, Falter U
- Issue date: 2007 Mar